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MicroRNAs (miRNAs) are important modulators of eukaryotic gene expression. By targeting protein coding transcripts,
miRNAs influence the cellular transcriptome and proteome, thus helping to determine cell fate. MiRNAs have emerged
as crucial molecules in cancer research, in which recent studies have linked erratic expression of miRNAs to
carcinogenesis and have provided solid evidence for their potential in cancer therapy. This review briefly
summarises the recent knowledge on the involvement of miRNAs in tumourigenesis and reviews current
studies on the therapeutic strategies and advances in the delivery of miRNAs.
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MicroRNAs (miRNAs) are endogenous, small, noncoding
RNAs that are highly conserved across various species of eu-
karyotes [1]. MiRNAs repress cellular translation and stability
of a myriad of protein-coding transcripts by primarily targeting
their 3′ untranslated regions (UTRs) in a sequence-specific
manner [2, 3]. This selective silencing of gene expression by
miRNAs has profound impact on human health and disease.
The latest release of miRBase [4] enlists at least 2588
miRNAs in humans. The canonical biogenesis of miRNAs
is a tightly regulated process. Various epigenetic, transcrip-
tional and processing mechanisms fine-tune the spatial and
temporal expression of miRNAs [5]. MiRNA genes are pre-
dominantly transcribed by RNA polymerase II as primary
miRNAs (pri-miRNAs) which are processed to precursor
miRNAs (pre-miRNAs) in the nucleus by a microprocessor
complex (composed of Drosha and DGCR8 (DiGeorge syn-
drome critical region 8)) [6]. Subsequently, pre-miRNAs
are exported to the cytoplasm by Exportin-5-Ran-GTP
complex [7], where Dicer1 cleaves the hairpin loop of pre-
miRNA [8, 9] and TARBP2 (TAR RNA-binding protein 2)
facilitates RNA duplex loading onto Argonaute protein
AGO2 [10]. The antisense strand (mature) is retained by
AGO2 and the sense strand is degraded, thus configuring a
silencing complex [11] (Fig. 1). Non-canonical miRNA* Correspondence: michela.garofalo@cruk.manchester.ac.uk
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are reviewed elsewhere [12].
MiRNAs silence gene expression via multiple mecha-
nisms [13]. The current model suggests that miRISC
(miRNA-induced silencing complex) binds to the comple-
mentary “seed” region within the 3′ UTR of target
mRNAs (messenger RNAs) and influences their degrad-
ation and/or the level of translation [3]. The thermo-
dynamic stability of the miRNA-mRNA interaction is
critical for effective repression of a potential target; how-
ever, other factors, including RNA secondary structure
and spatial constraints posed by the same or other miRNA
binding sites within the 3′ UTR, may influence the silen-
cing outcome of the target [14] (Fig. 1). Exponentially
growing evidence confers the unique potential of miRNAs
to modulate diverse biological processes, including cell
growth and proliferation, cell cycle control, differentiation,
apoptosis and tissue development [15, 16]. Therefore, it is
highly plausible that any aberration or deregulation in
miRNA expression can be detrimental to the cell. Further,
numerous studies have intimately linked erratic miRNA
expression to the aetiology of cancer. Here, we briefly
summarise the recent evidence for the involvement of
miRNAs and miRNA-based therapeutic strategies in vari-
ous cancers. Also, we highlight advances on the thera-
peutic delivery of miRNAs for the treatment of cancer.
MiRNAs in cancer: a friend and foe
The role of miRNAs in cancer was first reported by Calin
et al. in chronic lymphocytic leukaemia [17]. Subsequently,ticle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 The majority of miRNA genes are transcribed by the RNA polymerase II (Pol II) as primary miRNAs (pri-miRNAs) which are processed to
precursor miRNAs (pre-miRNAs) via the Drosha-DGR8 complex. Pre-mRNAs are exported to the cytoplasm by Exportin-5-Ran-GTP (Xpo-5-RanGTP)
where Dicer1 cleaves the hairpin loop and Tar RNA-binding protein 2 (TARBP2) facilitates the RNA duplex loading onto Argonaute protein AGO2.
AGO2 and the mature strand enter a protein effector complex formed by the RNA-induced silencing complex (miRISC). The miRNA guides the
RISC to messenger RNA targets causing either mRNA cleavage (perfect complementarity) or translational repression (imperfect complementarity)
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pression of miRNAs in the hallmarks of cancer [18].
Diverse cellular mechanisms contribute to miRNA deregu-
lation in cancer, and genetic changes [19], aberrant DNA
methylation [20] and histone acetylation [21] have been at-
tributed to miRNA deregulation. Importantly, cancer-
related transcription factors such as myc [22] and p53 [23]
have been shown to influence miRNA expression. Add-
itional mechanisms including alternative splicing, polyade-
nylation and mutations in miRNA processing machinery
may also hamper miRNA maturation [24]. Aberrant loss or
gain of miRNAs contributes to initiation, progression, me-
tastasis and drug resistance of a wide spectrum of cancers.
Depending on the genes and/or pathways they affect, miR-
NAs can act as tumour suppressors or oncogenes in a
tissue-specific manner. For example, let-7 family miRNAs
are known to be tumour suppressors. Downregulation of
let-7 expression has been reported in head, neck, lung,
breast, ovarian and prostate cancers [25]. Let-7 negatively
regulates oncogenes such as KRAS, c-MYC, CDK6,
HOXA9, TGFBR1, BCL-XL and MAP4K3, thereby pro-
moting anti-oncogenic pathways [26]. Similarly, miR-34
family [27], miR-223 [28], miR-143/145 cluster [29, 30]
and miR-204 [31] are commonly downregulated in variouscancers; interestingly, reconstitution of respective miRNAs
in these studies significantly reduced tumour growth. Inter-
estingly, miR-214 is oncogenic in osteosarcoma [32] and
nasopharyngeal cancer [33], whereas it appears to be a
tumour suppressor in glioma [34] and colorectal cancer
[35]. Similarly, miR-125b displays an oncogenic phenotype
in colon and haematopoietic cancers, whereas it acts as a
tumour suppressor in breast cancer and hepatocellular
carcinoma [36]. Additional miRNAs, namely miR-17/92
cluster, miR-21, miR-155, miR-221, miR-222 and miR-9 are
upregulated in various cancers [37]. Elevated miR-17/92
levels caused oncogenic activation of PI3K and NF-kB sig-
nalling in lymphomas [38]. MiR-21 overexpression has a
causal role in tumourigenesis of pre-B cell lymphomas [39].
MiR-155 inhibition restored expression of tumour suppres-
sor TP53INP1 and inhibited tumour development in breast
cancer [40]. The intimate role of miRNAs in tumour
metastasis, drug resistance and cancer stemness has been
discussed elsewhere [41]. A more recent update on the role
of miRNAs in various cancers has been tabulated (Table 1).
Taken together, dysregulated miRNA expression appears to
influence various hallmarks of cancer. A comprehensive
understanding of miRNA biology in carcinogenesis can
possibly pave novel routes for anti-cancer therapy.
Table 1 A list of miRNAs involved in various cancer types. Corresponding functional role (phenotype) and validated targets (targets)
are shown in separate columns
Cancer miRNA Phenotype Targets Reference
Lung cancer miR-132/212 TS CyclinD1 [72]
(NSCLC) miR-124 TS SOX8 [73]
miR-126 TS VEGF-PI3K-Akt-MRP1 [74]
miR-181 TS Bcl2 [75]
miR-34a TS TGFβR2 [76]
miR-145 TS Oct-4 [77]
miR-21 OG PDCD4 [78]
miR-137 PM SLC22A18 [79]
Gastro-intestinal cancers
Gastric cancer miR-335 TS RASA1 [80]
miR-374b-5p OG RECK [81]
miR-490-3p OG SMARCD1 [82]
miR-199a-3p OG ZHX1 [83]
Colorectal cancer miR-185 TS-PM STIM1 [84]
miR-92a OG-PM PTEN [85]
miR-7 TS-PM EGFR [86]
Hepatocellular carcinoma miR-9 PM [87]
miR-150-5p TS MMP14 [88]
miR-21 OG-PM AP1 [89]
miR-122 TS Hnf4α-GALNT10-EGFR [90]
miR-486-5p TS PIK3R1 [91]
Esophageal cancer miR-101, miR-127 TS MALAT1 [92]
miR-126 TS DNMT1/ADAM9-EGFR [93]
miR-27a TS K-Ras [94]
Haematological cancers
Lymphoma miR-155-3p, TS LT-β [95]
miR-224 TS-PM CD59 [96]
miR-17-92 OG Sin3b, Hbp1, Suv420h1, Btg1, Bim [97]
Leukaemia miR-486-5p OG AKT-FOXO1 [98]
miR-22 OG PTEN [99]
miR-638 TS CDK2 [100]
Reproductive cancers
Cervical cancer miR-126 TS-PM PTEN [101]
miR-21, Let-7a OG/TS STAT3 [102]
miR-375 DR E-cadherin [103]
Prostate cancer miR-3195, miR-374b TS HIF-1α, HIF-2α and VEGF [104]
miR-218 TS TPD52 [105]
miR-449b PM [106]
Breast cancer miR-873 TS-DR ERα–CDK3 [107]
miR-18b, miR-103, miR-107 and miR-652 PM [108]
miR-7 TS-DR EGFR, Src kinase [109]
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Table 1 A list of miRNAs involved in various cancer types. Corresponding functional role (phenotype) and validated targets (targets)
are shown in separate columns (Continued)
Glioblastoma miR-125a-5p TS TAZ [110]
miR-155 OG-DR MAPK13 and MAPK14 [111]
miR-449a TS MAZ [112]
miR-148a TS Oct4, Sox-2 [113]
Abbreviations: NSCLC non-small cell lung cancer; TS tumour suppressor; OG oncogenic; PM prognostic marker; DR drug resistance
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MiRNAs are ubiquitously deregulated, as a cause or con-
sequence, in virtually all cancers. By modulating multiple
targets or entire pathways, and by having unique expres-
sion profiles and higher stability in biological samples,
miRNAs have quickly gained diagnostic and therapeutic
value. Modulating miRNA expression for cancer therapy
is currently under investigation; in general, the thera-
peutic modulation of miRNAs is achieved by inhibiting
oncogenic miRNAs, or by reconstituting tumour sup-
pressor miRNAs. In recent years, the therapeutic poten-
tial of miRNAs in cancer has been demonstrated in
several published studies (Table 1). For this review, we
only focus on the most recent in vivo and preclinical stud-
ies which employed, either alone or in combination with
conventional drugs, miRNAs as active agents against vari-
ous cancers.
Xue et al. demonstrated that targeted delivery of miR-
34a and K-ras siRNA into a murine lung cancer model
resulted in significant tumour regression. Reconstitution
of miR-34a reduced the mRNA levels of oncogenes such
as Ccnd1, Sirt1, Cdk6 and Ccne2. Furthermore, modu-
lating RNA delivery combined with cisplatin prolonged
mice survival in this model [42]. In an independent
study, combined reconstitution of miR-34 and let-7 re-
duced the expression of the tumour promoters Lin28b,
c-Met and Myc and, as a consequence, tumour growth
was drastically decreased in a murine model of non-
small cell lung cancer (NSCLC) [43]. Another study
reported that restoring miR-200c in a xenograft model
enhanced sensitivity of lung tumours to radiation by tar-
geting the expression of DNA repair protein RAD51 and
oxidative stress response genes peroxiredoxin-2, Nrf2
and SESN1 [44]. Together, these in vivo models strongly
support miRNAs as novel therapeutic options, either
alone or in combination, for treating deadly lung cancers
which are often presented with few treatment options.
Interestingly, two independent studies have demon-
strated that targeted delivery of miR-520e [45] and miR-
375 [46] dramatically reduced liver cancer cell growth in
in vivo xenograft models. Independently, ectopic expres-
sion of miR-217 significantly reduced tumour growth in a
pancreatic ductal adenocarcinoma (PDAC) xenograft
model [47]. Conversely, knockdown of oncogenic miR-21
expression combined with gemcitabine has been shown tobe effective in controlling pancreatic ductal adenocarcin-
oma in a mouse model [48]. In addition, forced expression
of miR-25 into a colon cancer mice model markedly re-
duced tumour burden [49]. Intriguingly, miR-182 expres-
sion promoted metastasis by modulating the expression of
endothelial-mesenchymal transition (EMT) components
in colorectal cancer; however, inhibition of miR-182 re-
versed this effect [50]. Taken together, these studies war-
rant the therapeutic benefits of miRNAs in the treatment
of various gastro-intestinal cancers.
Liu et al. have shown that targeted downregulation of
miR-106b-5p and its targets retinoblastoma-like 1 and 2
(RBL1, 2) and caspase-8 inhibited glioma formation in a
xenograft mice model [51]. Conversely, ectopic expression
of miR-1 in glioblastoma-derived extracellular vesicles
halted tumour growth, neovascularization and invasive-
ness [52]. Also, miR-142-3p overexpression modulated
cytokine signalling in disease-associated infiltrating mac-
rophages, resulting in glioma tumour growth inhibition
[53]. These reports highlight the beneficial role of miR-
NAs in otherwise untreatable glioma.
Specific knockdown of miR-20b in a breast cancer nude
mice model has shown to suppress tumour growth in vivo
[54]. Intriguingly, a recent study demonstrated that in vivo
delivery of miR-31 resulted in increased sensitivity for pac-
litaxel in an ovarian cancer model [55]. In the light of
above studies, modulating miRNA expression appears to
be a promising strategy for cancer therapy; however, ca-
veats such as off-target effects, functional redundancy and
dual nature (tumour promoter and tumour suppressor)
should be considered carefully before utilising miRNAs
for anti-cancer therapies.
MiRNAs in cancer therapy: the challenge
Successful translation of miRNAs into cancer therapeu-
tics heavily depends on the specific, efficient and safe
delivery of miRNA modulators to the tumour sites. Vari-
ous biological barriers including in vivo nuclease degrad-
ation, fibrous nature of tumours, insufficiency of miRNA
processing machinery and miRNA-induced immune re-
sponse drastically hinder the bioavailability of ectopic
miRNAs. Multiple approaches are in rapid development
to circumvent these delivery hurdles. Chemical modifica-
tions on 2′-OH ribose [56] or phosphate backbone (locked
nucleic acids, or LNAs) [57] made synthetic miRNAs less
Table 2 A summary of various miRNA delivery methods and
their potential modulatory effects
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stability and affinity to the target sequence. Various strat-
egies have been developed for efficient delivery of miRNA
modulators. Lentiviral, adenoviral and adeno-associated
viral (AAVs) vectors expressing miRNA antagonists or
mimics have proven to be effective delivery systems in
various cancer models [58]. Importantly, cell-specific moi-
eties can be engineered onto the viral capsid to enhance
specificity uptake by cancer cells [59]. Non-integrating
AAVs were successfully used as vehicles for miRNA re-
placement therapy in liver cancer [60]. Recently, exosomes
and vesicles released by virus-infected cells have been
shown to encapsulate and deliver miRNAs into the target
cells, indicating that viral-derived exosomes can be
exploited for miRNA delivery [61]. Another approach of
vectors expressing tandem repeats of miRNA antisense se-
quences, termed miRNA sponges, can de-repress miRNA
targets and have shown to be effective in modulating
miRNA expression in vitro and in vivo [62], [63]. This ap-
proach offers a unique opportunity to target a family of
miRNAs sharing the same seed sequence. A recent study
engineered a vector expressing miRNA sponges and
claims that this vector could circumvent some of the tech-
nical problems associated with this method [64]. Techno-
logical and engineering advancements have generated a
variety of nanomaterials for miRNA delivery. Specifically,
nanosized gold, carbon and silica particles have been used
as carriers for miRNAs. Recently, systemic delivery of
miR-34a-silica nanoparticles coated with tumour-specific
antibody led to significant tumour growth inhibition and
enhanced apoptosis in neuroblastoma [65]. Similarly,
owing to their biodegradable property and high electro-
static affinity towards cellular membranes, cationic poly-
mers have become an attractive option for miRNA
transport. Poly-lacticco-glycolic acid (PLGA), polyethyle-
nimine (PEI) and poly-dimethylaminoethyl methacrylate
(PDMAEMA) are common cationic polymers used in nu-
cleic acid delivery for cancer therapy. For example, sys-
temic delivery of PLGA-based miR-21 and miR-10b
antagonists in a breast cancer model caused dramatic ef-
fects on tumour regression [66]. Encouragingly, PEI-based
miR-145 nanoparticles combined with radiation and
chemotherapy significantly eliminated metastatic tumour
nodules in a lung adenocarcinoma mice model [67]. Fur-
thermore, Trang et al. successfully delivered lipid nanopar-
ticles harbouring miR-34a or let-7 mimics which reduced
tumour size in a K-ras-activated NSCLC mouse model
[68]. Recently, advances in nanotechnology have led to an
integrated diagnostic and therapeutic platform called
“nanotheranostics” [69]. This novel system offers a unique
possibility to load both diagnostic and therapeutic agents
onto a single nanoparticle, thus facilitating to monitor the
distribution, release and efficacy of drug in real time.
Given the immense potential of miRNAs as biomarkersand therapeutic molecules, miRNA-based nanotheranos-
tics could open novel avenues for personalised medicine
in cancer therapy. Although current miRNA delivery
methods (Table 2) have been promising in various experi-
mental models, each of these systems suffers from various
limitations. Despite the high transfection efficacy, viral-
based delivery methods may elicit immune/inflammatory
response, and may also suffer from the risk of integrating
into the host genome, leading to oncogenic insertional
mutagenesis. Nevertheless, advanced genetic engineering
methods may lead to improved safety profiles for further
exploiting these methods for therapeutic miRNA delivery.
On the other hand, challenges such as cytotoxicity, non-
specific tissue distribution and high cost of production re-
mains to be addressed for the nanoparticle-based delivery
platforms. Therefore, a reliable, safe and cost-effective
miRNA delivery strategy would largely be beneficial for
exploiting miRNAs for clinical purposes.
Future perspectives
Given the heterogeneous nature of the disease and the
limitations facing conventional therapies, cancer therapy
needs to be multidimensional. Research so far has un-
doubtedly established the potential of miRNAs in diagno-
sis, therapy and prognosis of cancer. Successful in vivo
and preclinical studies have appreciated the therapeutic
potential of miRNAs for cancer treatment. For instance,
restoring the expression of miRNAs such as Let 7, miR-16
and miR-31 has shown to have anti-cancer effects in vari-
ous preclinical models [70]. Thus far, studies have pro-
posed several miRNAs as potential candidates for cancer
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sor miRNA, appears to be promising. Ectopic expression
of miR-34 has shown to have therapeutic benefits for a
variety of cancers [27]. Moreover, a liposome-based
mimic of miR-34 (MRX34) developed by Mirna Ther-
apeutics recently progressed into phase I clinical trials
(identifier: NCT01829971). The outcome of this trial (due
in December 2015) may hopefully provide more insights
into this novel paradigm. Although technical challenges
remain to be addressed, miRNA therapeutics appear to
hold huge promise for cancer treatment, at least for those
cancers where other treatment options have plateaued.
Comprehensive understanding of the role of miRNAs in
complex regulatory networks involved in cancer may help
with designing combinatorial therapeutic strategies. Fur-
ther developments in miRNA delivery technologies will
hopefully translate miRNA-based cancer therapeutics into
a clinical reality.
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